Hepatic DNA adduct dosimetry in rats fed tamoxifen: A comparison of methods

Mutagenesis

Volumn 20, Issue 2, 2005, Pages 115-124

  Schild, Laura J ^a   Phillips, David H ^b   Osborne, Martin R ^b   Hewer, Alan ^b   Beland, Frederick A ^c   Churchwell, Mona I ^c   Brown, Karen ^d   Gaskell, Margaret ^d   Wright, Elizabeth ^d   Poirier, Miriam C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (DEOXYGUANOSIN N2 YL) N DESMETHYLTAMOXIFEN; DNA; HEPATIC DNA; NORTAMOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DNA ADDUCT; DOSE RESPONSE; DOSIMETRY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMILUMINESCENT MEASUREMENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LIVER; RATS; RATS, INBRED F344; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TAMOXIFEN;

ANIMALIA;

EID: 21044450818     PISSN: 02678357     EISSN: None     Source Type: Journal    
DOI: 10.1093/mutage/gei015     Document Type: Article

References (45)

1. Clemons,M., Danson,S. and Howell,A. (2002) Tamoxifen ('Nolvadex'): a review. Cancer Treat. Rev., 28, 165-180.
2. Brown,K. (2002) Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. Expert Opin. Drug Saf., 1, 253-267.
3. Smith,R.E. and Good,B.C. (2003) Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others. Endocr. Relat. Cancer, 10, 347-357.
4. White,I.N.H. (2003) Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr. Drug Metab., 4, 223-239.
5. IARC (1996) Tamoxifen. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 66, Some Pharmaceutical Drugs. IARC, Lyon, France, pp. 253-365.
6. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351, 1451-1467.
7. Cuzick,J., Powles,T., Veronesi,U., Forbes,J., Edwards,R., Ashley,S. and Boyle,P. (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet, 361, 296-300.
8. Kloos,I., Delaloge,S., Pautier,P., Di Palma,M., Goupil,A., Duvillard,P., Cailleux,P.E. and Lhomme,C. (2002) Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int. J. Gynecol. Cancer, 12, 496-500.
9. Curtis,R.E., Freedman,D.M., Sherman,M.E. and Fraumeni, J.F., Jr (2004) Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J. Natl. Cancer. Inst., 96, 70-74.
10. White,I.N.H., de Matteis,F., Davies,A., Smith,L.L., Crofton-Sleigh,C., Venitt,S., Hewer,A. and Phillips,D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
11. Greaves,P., Goonetilleke,R., Nunn,G., Topham,J. and Orton,T. (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
12. White,I.N.H. (1999) The tamoxifen dilemma. Carcinogenesis, 20, 1153-1160.
13. Phillips,D.H. (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis, 22, 839-849.
14. Hemminki,K., Rajaniemi,H., Lindahl,B. and Moberger,B. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56, 4374-4377.
15. Carmichael,P.L., Ugwumadu,A.H.N., Neven,P., Hewer,A., Poon,G.K. and Phillips,D.H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res., 56, 1475-1479.
16. 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis, 20, 339-342.
17. Shibutani,S., Suzuki,N., Terashima,I., Sugarman,S.M., Grollman,A.P. and Pearl,M.L. (1999) Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol., 12, 646-653.
18. Shibutani,S., Ravindernath,A., Suzuki,N., Terashima,I., Sugarman,S.M., Grollman,A.P. and Pearl,M.L. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis, 21, 1461-1467.
19. Martin,E.A., Brown,K., Gaskell,M., Al-Azzawi,F., Garner,R.C., Boocock,D.J., Mattock,E., Pring,D.W., Dingley,K., Turteltaub,K.W., Smith,L.L. and White,I.N.H. (2003) Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res., 63, 8461-8465.
20. 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J. Natl Cancer. Inst., 96, 1099-1104.
21. Poirier,M.C. and Schild,L.J. (2003) The genotoxicity of tamoxifen: extent and consequences, Kona, Hawaii, January 23, 2003. Mutagenesis, 18, 395-399.
22. Foster,A.B., Jarman,M., Leung,O.-T., McCague,R., Leclercq,G. and Devleeschouwer,N. (1985) Hydroxy derivatives of tamoxifen. J. Med. Chem., 28, 1491-1497.
23. Boocock,D.J., Maggs,J.L., Brown,K., White,I.N.H. and Park,B.K. (2000) Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of α-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts. Carcinogenesis, 21, 1851-1858.
24. Osborne,M.R., Hewer,A. and Phillips,D.H. (2001) Resolution of α-hydroxytamoxifen; R-isomer forms more DNA adducts in rat liver cells. Chem. Res. Toxicol., 14, 888-893.
25. Osborne,M.R., Hewer,A., Hardcastle,I.R., Carmichael,P.L. and Phillips,D.H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56, 66-71.
26. 32P-postlabeling. Cancer Res., 59, 4829-4833.
27. Phillips,D.H., Carmichael,P.L., Hewer,A., Cole,K.J., Hardcastle,I.R., Poon,G.K., Keogh,A. and Strain,A.J. (1996) Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis, 17, 88-94.
28. Phillips,D.H., Hewer,A., Horton,M.N., Cole,K.J., Carmichael,P.L., Davis,W. and Osborne,M.R. (1999) N-Demethylation accompanies α-hydroxylation in the metabolic activation of tamoxifen in rat liver cells. Carcinogenesis, 20, 2003-2009.
29. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis, 7, 1543-1551.
30. 32P-post-labelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method. Carcinogenesis, 19, 1061-1069.
31. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis, 16, 1299-1304.
32. Beland,F.A., Fullerton,N.F. and Heflich,R.H. (1984) Rapid isolation, hydrolysis and chromatography of formaldehyde-modified DNA. J. Chromatogr., 308, 121-131.
33. Gamboa da Costa,G., Marques,M.M., Freeman,J.P. and Beland,F.A. (2003) Synthesis and investigation of α-hydroxy-N,N-didesmethyltamoxifen as a proximate carcinogen in the metabolic activation of tamoxifen. Chem. Res. Toxicol., 16, 1090-1098.
34. Gamboa da Costa,G., Marques,M.M., Beland,F.A., Freeman,J.P., Churchwell,M.I. and Doerge,D.R. (2003) Quantification of tamoxifen-DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry. Chem. Res. Toxicol., 16, 357-366.
35. Brown,K., Heydon,R.T., Jukes,R., White,I.N.H. and Martin,E.A. (1999) Further characterizarion of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen. Carcinogenesis, 20, 2011-2016.
36. Gamboa da Costa,G., Hamilton,L.P., Beland,F.A. and Marques,M.M. (2000) Characterization of the major adduct formed by α-hydroxy-N- desmethyltamoxifen in vitro and in vivo. Chem. Res. Toxicol., 13, 200-207.
37. Gamboa da Costa,G., McDaniel-Hamilton,L.P., Heflich,R.H., Marques,M.M. and Beland,F.A. (2001) DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis, 22, 1307-1315.
38. Umemoto,A., Komaki,K., Monden,Y., Suwa,M., Kanno,Y., Kitagawa,M., Suzuki,M., Lin,C.-X., Ueyama,Y., Momen,M.A., Ravinderath,A. and Shibutani,S. (2001) Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice. Chem. Res. Toxicol., 14, 1006-1013.
39. Schild,L.J., Divi,R.L., Beland,F.A., Churchwell,M.I., Doerge,D.R., Gamboa da Costa,G., Marques,M.M. and Poirier,M.C. (2003) Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res., 63, 5999-6003.
40. Shibutani,S., Suzuki,N., Laxmi,Y.R.S., Schild,L.J., Divi,R.L., Grollman,A.P. and Poirier,M.C. (2003) Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res., 63, 4402-4406.
41. Kim,S.Y., Suzuki,N., Laxmi,Y.R.S., Rieger,R. and Shibutani,S. (2003) α-Hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem. Res. Toxicol., 16, 1138-1144.
42. Davis,W., Hewer,A., Rajkowski,K.M., Meinl,W., Glatt,H.R. and Phillips,D.H. (2000) Sex differences in the activation of tamoxifen to DNA binding species in rat liver in vivo and in rat hepatocytes in vitro: role of sulphotransferase induction. Cancer Res., 60, 2887-2891.
43. Rajkowski,K.M., Robel,P. and Baulieu,E.-E. (1997) Hydroxysteroid sulfotransferase activity in the rat brain and liver as a function of age and sex. Steroids, 62, 427-436.
44. Kim,S.Y., Suzuki,N., Laxmi,Y.R.S. and Shibutani,S. (2004) Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab. Rev., 36, 199-218.
45. Umemoto,A., Monden,Y., Lin C.-X., Momen,M.A., Ueyama,Y., Komaki,K., Laxmi,Y.R.S. and Shibutani,S. (2004) Determination of tamoxifen-DNA adducts in leukocytes from breast cancer patients treated with tamoxifen. Chem. Res. Toxicol., 17, 1577-1583.